Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)

v3.22.1
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
1 Months Ended 3 Months Ended
Jan. 31, 2010
contingent_value_right
contingent_value_right_series
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Number of CVR Series | contingent_value_right_series 4    
Transferred over Time | Phase 3 Clinical Trial      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Gross contract asset   $ 10,000,000  
Maximum | Transferred over Time | Development, Regulatory, & Commercial Milestones and Tiered Royalties      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Investments   375,000,000  
Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Number of CVRs issued per acquiree share | contingent_value_right 4    
Number of CVRs issued from each CVR series | contingent_value_right 1    
Frequency of cash payments to CVR holders 6 months    
xCella | Earnout Rights for Partner Research and Development      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Earnout rights recognized   500,000  
Contingent liabilities - Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Mark-to-market adjustment of CVR liability   600,000  
Contingent liabilities - Icagen      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Payment for contingent consideration liabilities   1,500,000  
Recurring      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   189,006,000 $ 321,586,000
Liabilities, fair value   9,047,000 11,157,000
Recurring | Contingent liabilities - CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   334,000 349,000
Recurring | Contingent liabilities - Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   2,782,000 3,358,000
Recurring | Contingent liabilities - Icagen      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   5,376,000 7,364,000
Recurring | Contingent liabilities - xCella      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   480,000 0
Recurring | Amounts owed to former licensor      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   75,000 86,000
Recurring | Short-term investments      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   168,861,000 290,697,000
Recurring | Investment in Viking common stock      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   20,145,000  
Recurring | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   26,424,000 40,624,000
Liabilities, fair value   75,000 86,000
Recurring | Level 1 | Contingent liabilities - CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 1 | Contingent liabilities - Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 1 | Contingent liabilities - Icagen      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 1 | Contingent liabilities - xCella      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 1 | Amounts owed to former licensor      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   75,000 86,000
Recurring | Level 1 | Short-term investments      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   6,279,000 9,735,000
Recurring | Level 1 | Investment in Viking common stock      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value     30,889,000
Recurring | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   162,394,000 280,553,000
Liabilities, fair value   2,782,000 3,358,000
Recurring | Level 2 | Contingent liabilities - CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 2 | Contingent liabilities - Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   2,782,000 3,358,000
Recurring | Level 2 | Contingent liabilities - Icagen      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 2 | Contingent liabilities - xCella      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 2 | Amounts owed to former licensor      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 2 | Short-term investments      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   162,394,000 280,553,000
Recurring | Level 2 | Investment in Viking common stock      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   0 0
Recurring | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   188,000 409,000
Liabilities, fair value   6,190,000 7,713,000
Recurring | Level 3 | Contingent liabilities - CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   334,000 349,000
Recurring | Level 3 | Contingent liabilities - Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 3 | Contingent liabilities - Icagen      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   5,376,000 7,364,000
Recurring | Level 3 | Contingent liabilities - xCella      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   480,000 0
Recurring | Level 3 | Amounts owed to former licensor      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Level 3 | Short-term investments      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   188,000 409,000
Recurring | Level 3 | Investment in Viking common stock      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   $ 0 $ 0